Ceftriaxone as an Alternative Therapy for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia after Initial Clearance of Bloodstream Infection

Table 1

Baseline demographics.

Variable presented as #(%) or median (IQR)	Ceftriaxone (n = 20)	SOCT (n = 23)	value
Age	43.5 [35.25–57.5]	45 [36–55]	0.715
Sex, male	10 (50)	17 (73.9)	0.106
Race
White	9 (45)	9 (39.1)	0.697
Black	11 (55)	14 (60.9)	0.697
Previous hospital stay within 6 months	7 (35)	7 (30.4)	0.750
Co-morbidities
Diabetes mellitus	10 (50)	9 (39.1)	0.474
Hypertension	9 (45)	15 (65.2)	0.183
Congestive heart failure	3 (15)	5 (21.7)	0.704
COPD	0 (0)	1 (4.3)	1.000
Chronic kidney disease	2 (10)	8 (34.8)	0.076
Persons who inject drugs	2 (10)	5 (21.7)	0.420
Immunocompromised	3 (15)	5 (21.7)	0.704
Major surgical procedure	7 (35)	2 (8.7)	0.059

COPD = chronic obstructive pulmonary disease.